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ABSTRACT
Background: The novel biomarker human epididymis protein 4 (HE4) shows prognostic value in acute
heart failure (HF) patients. We measured HE4 levels in patients with chronic heart failure (CHF) and cor-
related them to HF severity, kidney function, and HF biomarkers, and determined its predictive value.
Methods: Serum HE4 levels in patients (n = 101) with stable CHF with reduced left ventricular ejection
fraction (LVEF <45%) from the Vitamin D CHF (VitD-CHF) study (NCT01092130) were compared with
those in age- and sex-matched healthy control subjects (n = 58) from the Prevention of Renal and Vascu-
lar End-Stage Disease (PREVEND) study.
Results: HE4 levels were higher in CHF compared with control subjects (69.2 pmol/L [interquartile range
55.6-93.8] vs 56.1 pmol/L [46.6-69.0]; P < .001) and were higher with increasing New York Heart Asso-
ciation functional class. Levels were associated with HF risk factors, including age, gender, diabetes, smoking
and N-terminal prohormone of B-type natriuretic peptide (NT-proBNP). HE4 demonstrated strong asso-
ciations with kidney function and HF fibrosis biomarkers. In a multivariable model, we identified creatinine,
NT-proBNP, galectin-3, high-sensitive troponin T, and smoking as factors associated with HE4. Indepen-
dently from these factors, HE4 levels predicted death and HF rehospitalization (5-year follow-up, hazard
ratio 3.8; confidence interval 1.31–11.1; P = .014).
Conclusions: HE4 levels are increased in CHF, correlate with HF severity and kidney function, and predict
HF outcome. (J Cardiac Fail 2017;23:12–19)
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Heart failure (HF) is a major health problem in the Western
world. With increasing prevalence, high morbidity, and 5- and
10-year mortality of 50% and 90%, respectively, HF has enor-
mous social and economic consequences within our society.1
HF is usually preceded by various cardiovascular diseases,
including myocardial infarction, hypertension, atrial fibril-
lation, and valvular diseases, that provoke structural,
morphologic, and functional changes of the heart, common-
ly referred to as cardiac remodeling.2,3
HF is a clinical syndrome, but besides signs and symp-
toms, circulating HF biomarkers can be helpful in diagnosis
of HF and could improve risk stratification and guide treat-
ment, as has been shown for N-terminal prohormone of B-type
natriuretic peptide (NT-proBNP).4–6 Until now, NT-proBNP is
the HF biomarker that is used for diagnostic and prognostic
purposes and has been included in the HF guidelines of the
European Society of Cardiology (ESC) and the guidelines of
the American Heart Association (AHA).7,8 New biomarkers
under investigation have been shown to reveal underlying pro-
cesses, and may potentially help in patient-tailored therapy.
Examples include fibroblast growth factor 23 (FGF-23),9 in-
flammatory biomarkers such as C-reactive protein and
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interleukin-6,6 and fibrotic biomarkers such as galectin-3
(Gal-3)6,10 and soluble suppression of tumorigenicity 2 (sST2).11
Recently, we reported that circulating human epididymis
protein 4 (HE4) levels in acute heart failure (AHF) patients
are correlated with HF severity and kidney function and were
strongly predictive of HF outcome.12 HE4, also known as whey
acidic protein four–disulfide core domain 2 (WFDC2), was
originally identified as a secretory protein present in the human
epididymis.13–15 Later studies showed expression of HE4 in
multiple tissues throughout the body, including kidney, re-
spiratory tract, and other organs.13–15 HE4 levels are also
elevated in patients with ovarian cancer,16 and the use of these
levels has been approved for monitoring epithelial ovarian
cancer. Although the exact function of HE4 is not yet known,
HE4 sequence shows similarity to proteinase inhibitors, which
suggests a functional role of HE4 in fibrosis formation.13,17
LeBleu et al showed that fibroblast-derived HE4 is a medi-
ator of kidney fibrosis.18 Matrix proteinase activity was
inhibited by HE4, and degradation of type 1 collagen by matrix
metalloproteinases was reduced. Other WFDC proteins have
been associated with fibrosis formation and inflammatory
processes.17 Because these processes also play a pivotal role
in pathologic cardiac remodeling, we decided to further in-
vestigate the association between HE4 levels and HF.
Previously we identified HE4 as a biomarker elevated in
patients with AHF. In these patients, HE4 levels correlated
with HF severity and kidney function and were predictive of
HF outcome.12 No data exist about HE4 and chronic heart
failure (CHF). Therefore, in the present study, the associa-
tion of HE4 levels with HF severity and other HF biomarkers
and kidney function was investigated in patients with CHF.
In addition, its predictive value regarding HF outcome was
analyzed.
Methods
Study Population
VitD-CHF Study. The Vitamin D Chronic Heart Failure
(VitD-CHF) study was designed to study the effects of vitamin
D (VitD) supplementation on plasma renin activity (PRA) in
patients with CHF with reduced ejection fraction. The VitD-
CHF study and its methods have been described in detail
elsewhere.19 In short, patients with CHF with left ventricu-
lar ejection fraction (LVEF) ≤45% receiving HF treatment
according to the ESC guidelines were enrolled in this study.
Optimal medical therapy was defined as being treated with
a β-blocker (unless contraindicated), an angiotensin-converting
enzyme (ACE) inhibitor or, in the case of ACE inhibitor in-
tolerance, an angiotensin receptor blocker (ARB), each on
a stable dose. Estimated glomerular filtration rate (eGFR)
<60 mL min−1 1.73 m−2 was an exclusion cirterion. In total,
101 patients were included in this trial. HE4 levels were de-
termined in baseline serum samples collected before treatment
with VitD started. Serum samples were stored at −80°C until
analysis and were available for all 101 patients. Patients were
followed for 5 years, and a composite end point of all-cause
mortality and HF rehospitalization was analyzed.
PREVEND. To compare HE4 levels between patients
with and without CHF, an age- and sex-matched control group
of non-HF subjects was composed from the Prevention of
Renal and Vascular End-Stage Disease (PREVEND) study.
The PREVEND study was designed to prospectively inves-
tigate the natural course of microalbuminuria and the relation
of microalbuminuria with future renal and cardiovascular dis-
eases, as described in detail elsewhere.20 In short, 85,421
subjects from the general population aged 28–75 years were
sent a questionnaire with questions regarding cardiovascu-
lar risk factors and morbidity and a vial to collect an early-
morning urine sample. In total, 40,856 subjects responded.
Subjects with diabetes mellitus and pregnant women were ex-
cluded. Subjects with a morning urinary albumin concentration
(UAC) >10 mg/L and a selection of subjects with a UAC
<10 mg/L were included, a total of 8592 subjects. Serum
samples were stored at −80°C until analysis. For the present
study, a control group of non-HF subjects was created as
follows: subjects with chronic heart disease and/or recorded
cardiac events, including history of myocardial infarction,
angina pectoris, coronary artery bypass grafting, and/or per-
cutaneous coronary intervention, were excluded. Also, subjects
with renal disease requiring dialysis and/or a creatinine clear-
ance <60 mL/min were excluded. After exclusion, out of 4268
suitable control subjects, 58 age- and sex-matched subjects
were randomly selected to form a suitable control group for
the VitD-CHF cohort.
Both the VitD-CHF study and the PREVEND study were
approved by the Ethics Committee of the University Medical
Center Groningen and performed in accordance with the dec-
laration of Helsinki. Every participant provided written
informed consent.
Measurement of HE4
Serum HE4 levels were measured with the use of an
enzyme-linked immunosorbent assay (ELISA; Fujirebio Di-
agnostics, Malvern, Pennsylvania). The Food and Drug
Administration approved the use of this ELISA to monitor
patients with ovarian cancer. This ELISA allows quantita-
tive measurements of HE4 levels in serum and has a detection
limit of ≤25 pmol/L and a coefficient of variance (CV) ≤15%.
Standard curves and control samples were included in du-
plicate on all plates. The lower control (expected value 38–
70 pmol/L, average measured value 55.33 ± 1.29 pmol/L) had
a CV of 2.3%. The upper control (expected value 304–455
pmol/L, average measured value 404.71 ± 21.65 pmol/L) had
a CV of 5.3%. Interassay reproducibility was 97.7%.
Laboratory Measurements and Definitions
On the day of the hospital visit for the VitD-CHF study,
routine laboratory measurements were performed, includ-
ing glycated hemoglobin (HbA1c), total cholesterol, low-
density lipoprotein (LDL), and albumin. NT-proBNP,
creatinine, and high-sensitivity troponin T (hsTnT) were mea-
sured with the use of the Roche Modular system (Roche,
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Mannheim, Germany). Gal-3 was measured with the use of
an ELISA (BG Medicine, Waltham, Massachusetts). Plasma
aldosterone was measured with the use of a solid-phase I-125
radioimmunoassay (Siemens Diagnostics, The Nether-
lands). Serum collagen type 1 cross-linked telopeptide (ICTP)
was measured with the use of a quantitative enzyme immu-
noassay (UniQ ICTP, Orion Diagnostica, Espoo, Finland).
Serum protocollagen 3 N-terminal propeptide (PIIINP) was
measured with the use of a quantitative radio immunoassay
(UniQ PIIINP; Orion Diagnostica). PRA was measured with
the use of an indirect radioimmunoassay kit for quantitative
determination of angiotensin I (Cisbio International, Codolet,
France). Plasma FGF-23 was measured with the use of an
ELISA (Immutopics, San Clemente, California). Body mass
index (BMI) was calculated by dividing weight by height
squared. Stroke volume (SV) was calculated by subtracting
left ventricular end-systolic volume (LVESV) from left ven-
tricular end-diastolic volume (LVEDV). LVEF was calculated
by dividing stroke volume (SV) by LVEDV. The simplified
Modification of Diet in Renal Disease formula was used to
calculate eGFR.
Statistical Analyses
Normality of data was analyzed with the use of the
Kolmogorov-Smirnov test combined with Q-Q plots. Nor-
mally distributed data are presented as mean ± SD.
Nonnormally distributed data are presented as median
(interquartile range [IQR]). Categoric variables are pre-
sented as percentages. Differences between 2 groups were
analyzed with the use of the independent-samples t test for
normally distributed data, the Mann-Whitney U test for
nonnormally distributed data, and the Fisher exact test for cat-
egoric variables. Univariate linear regression analysis was
performed on normally distributed data and log-transformed
nonnormally distributed data. Log-transformed HE4 data were
used in univariate regression analysis. Results are shown as
standardized β coefficient (Sβ), which reflects the change in
SD for the dependent variable for 1 SD change in the inde-
pendent variable, and R2, also known as the coefficient of
determination. Variables with a P value of ≤.30 in age-
adjusted univariate regression analysis were included in the
multivariate linear regression analysis. Forward selection was
used to compose a multivariable model. Log-transformed HE4
data were used also in multivariate linear regression analy-
sis. Results are shown as β ± SE and Sβ. The composite end
point (all-cause mortality or HF rehospitalization) for HE4
levels below and above median was depicted with the use of
Kaplan-Meier curves analyzed with log-rank tests. To cal-
culate the hazard ratios (HRs) and 95% confidence intervals
(CIs), the Cox proportional hazards model was used. As-
sumptions of proportional hazards were tested. Area under
the receiver operating characteristics curve (AUC) analysis
was used to determine the performance of HE4 as a prog-
nostic biomarker. With the use of a log-rank test for equality
of survivors, the expected versus observed event rates for the
HE4 median were determined. Statistical analysis was per-
formed with the use of SPSS software (IBM SPSS Statistics
version 22; IBM, Armonk, New York). A P value of <.05 was
considered to indicate statistical significance.
Results
Study Population and Baseline Characteristics
Patients with CHF and control subjects were matched for
age and sex (Table 1). In both the control group and the group
consisting of patients with HF, frequency distributions of HE4
levels showed nonnormal distributions (Fig. 1A and B), which
was confirmed by means of a Kolmogorov-Smirnov test.
Median HE4 levels were higher in patients with CHF (69.2
pmol/L, IQR 55.6–93.8) compared with control subjects (56.1
pmol/L, IQR 46.6–69.0; Fig. 1C). Moreover, HE4 levels were
higher in patients with higher New York Heart Association
(NYHA) functional class (NYHA III: 94.2 pmol/L, IQR 71.1–
137.9; NYHA II: 67.3 pmol/L, IQR 54.9–85.5), suggestive
of a relation between HE4 levels and HF severity (Fig. 1D).
This cohort did not contain NYHA IV patients. All patients
with HF and control subjects had serum HE4 levels above
the detection limit of 25 pmol/L of the HE4 ELISA.
Baseline characteristics of the total CHF cohort and as strati-
fied below and above the HE4 median are presented in Table 2.
All patients with HF were treated with ACE inhibitors or
ARBs, and nearly all were treated with β-blockers. Patients
with HE4 levels above the median were older and in a higher
NYHA functional class. Hypertension and smoking were more
prevalent in patients with high HE4 levels. Moreover, NT-
proBNP levels and levels of other HF-associated biomarkers,
including Gal-3, hsTnT, and ICTP, were higher in the group
above the median. Total cholesterol and LDL were, however,
lower in the high-HE4 group. Plasma creatinine levels were
significantly higher and eGFR lower in patients with high HE4.
No difference in HE4 levels in CHF of ischemic etiology (HE4
70.1 pmol/L, IQR 59.5–97.0; n = 73) versus nonischemic eti-
ology (HE4 65.2 pmol/L, IQR 50.6–89.6; n = 28) was observed
(P = .165).
Factors Associated With HE4
To further investigate which variables were associated, log-
transformed HE4 levels were used in linear regression analyses.
Both univariate and age-adjusted analyses were performed
(Table 3). Increasing age was a strong correlate of HE4
and explained 18.0% of the variance in HE4 levels. In
Table 1. Baseline Characteristics of Patients With Heart Failure
and Control Subjects
Characteristic
Control
(n = 58)
Heart Failure
(n = 101) P Value
Age (y) 63.7 ± 11.0 63.8 ± 10.0 .989
Male sex 54 (93.1%) 94 (93.1%) 1.000
Creatinine (μmol/L) 89.0 ± 25.5 90.0 ± 18.3 .789
HE4 (pmol/L) 56.1 (46.6–69.0) 69.2 (56.6–93.8) <.001
Data are presented as mean ± SD for normally distributed data, as median
(interquartile range) for nonnormally distributed data, and as n (%) for cat-
egoric variables. HE4, human epididymis protein 4.
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age-adjusted univariate regression analysis, NYHA functional
class, HF markers including NT-proBNP and Gal-3, and kidney
function markers, among others, remained significantly as-
sociated with HE4 levels.
In a stepwise regression selection we identified creati-
nine, NT-proBNP, Gal-3, hsTnT, and smoking as factors
associated with HE4. In this multivariable model, these factors
explained 59.5% of the variance in HE4 levels (Table 4). To
create a model including HF-related risk factors also, we
forced age, ischemic etiology, and LVEF in our multivari-
able model, which will be referred to as our clinical model
(Table 4).
HE4 and HF Outcome
Among 101 patients with CHF, 19 patients (20.9%) died and
13 (15.3%) HF hospitalizations were recorded in a follow-up
period of 5 years. The Kaplan-Meier curve for composite end
point (all-cause mortality or HF hospitalization) is shown in
Fig. 2. In patients with HE4 levels above the median, survival
was worse (P < .001). To adjust for the time to event, Cox re-
gression analyses were performed and the HRs are presented.
Patients with elevated HE4 levels showed a significant HR of
6.3 (CI 2.39–16.5; unadjusted P < .001).After adjusting for both
the multivariable model and the clinical model (including the
multivariable model and HF risk factors), HE4 remained a sig-
nificant predictor for events (HRs 4.3 [CI 1.50–12.5; P = .007]
and 3.8 [1.31–11.1; P = .014], respectively). Assumptions of
proportional hazards were upheld for all tested models.
To determine the performance of HE4 as a prognostic
biomarker, AUC analysis was performed. Solitary serum HE4
levels had an AUC of 0.733, which was better than the value
of 0.630 for NT-proBNP (Table 5). The AUC of the multi-
variable model was 0.807. Adding HE4 to this multivariable
model resulted in an AUC of 0.840. This was a nonsignifi-
cant increase of 3.3% (P = .245). With the use of the log-
rank test for equality of survivor functions, expected versus
observed event rates for the HE4 median were determined
and analyzed. More events than expected were observed in
the group of patients with HE4 levels above the HE4 median
(expected: 12.65 events; observed: 24 events). In the group
of patients with HE4 levels below the HE4 median, fewer
A B
C D
Fig. 1. Serum human epididymis protein 4 (HE4) levels in patients with heart failure (HF) and non-HF control subjects. (A) Frequency
distribution of HE4 levels in non-HF control subjects from PREVEND (n = 58). (B) Frequency distribution of HE4 levels in patients with
HF derived from the VitD-CHF cohort (n = 101). Bars indicate percentages within the respective study group. Bin width is 20 pmol/L. Center
of the first bin is 10 pmol/L. Center of the last bin is 210 pmol/L. (C) HE4 levels in patients with HF derived from the VitD-CHF cohort
(n = 101) and non-HF control subjects from PREVEND (n = 58). (D) HE4 levels in patients with HF derived from the VitD-CHF cohort
with New York Heart Association (NYHA) functional class II (n = 89) and III (n = 12) and non-HF control subjects from PREVEND (n = 58).
Bars indicate median. Error bars represent interquartile range. *P < .05 vs control group. #P < .05 vs NYHA II.
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events than expected were observed (expected: 16.35 events;
observed: 5 events; χ2 = 18.17; P < .001).
Discussion
This study is the first to show that HE4 levels are el-
evated in patients with CHF. We show that HE4 levels in
patients with CHF are correlated with HF risk factors in-
cluding age, male sex, hypertension, diabetes and HbA1c.
Importantly, strong correlations were observed with HF se-
verity, based on NYHA functional class and NT-proBNP levels,
and with other HF-associated biomarkers, including Gal-3,
FGF-23, hsTnT, and ICTP. Also, an association between HE4
and kidney function was observed. HE4 levels were higher
with decreasing renal function. A high HE4 level (above the
median) was associated with a higher risk of reaching the com-
posite end point, defined as HF hospitalization or all-cause
mortality, in this cohort of patients with CHF.
HE4 and Heart Failure
Previously, we reported that HE4 levels were associated
with HF severity and kidney function in patients with AHF.12
The results of the present study in patients with CHF are in
accordance with the data reported in patients with AHF and
again showed a strong association with NT-proBNP and Gal-
3. Several other studies showed that HE4 is associated with
renal diseases,14,21,22 and a correlation of HE4 and plasma cre-
atinine has been reported.23 In this study, we limited the patient
group to patients with an eGFR >60 mL min−1 1.73 m−2 to
limit the influence of this potential cofounding factor. Despite
this selection, a positive correlation with kidney function was
still observed. Both NT-proBNP and plasma creatinine levels
Table 2. Baseline Characteristics of VitD-CHF Cohort
Characteristic
Total
(n = 101)
Below-Median HE4
(n = 51)
Above-Median HE4
(n = 50) P Value
Age (y) 63.8 ± 10.0 60.8 ± 9.2 66.8 ± 10.0 .002*
Male, n (%) 94 (93.1%) 46 (90%) 48 (96%) .25
SBP (mm Hg) 116.4 ± 16.9 116.7 ± 14.2 116.0 ± 19.4 .83
DBP (mm Hg) 71.0 ± 10.6 71.1 ± 8.2 70.8 ± 12.6 .87
Hypertension 35 (34.7%) 12 (24%) 23 (46%) .018*
BMI (kg/m2) 28.0 ± 4.4 28.2 ± 3.8 27.7 ± 4.9 .60
Diabetes 14 (13.9%) 4 (8%) 10 (20%) .077
Current smoker 23 (22.8%) 7 (14%) 16 (32%) .029*
Myocardial infarction 73 (72.3%) 34 (67%) 39 (78%) .20
Hypercholesterolemia (%) 54 (53.5%) 27 (53%) 27 (54%) .92
Heart failure history
NYHA functional class
II 89 (88.1%) 50 (98%) 39 (78%) .002*
III 12 (11.9%) 1 (2%) 11 (22%)
LVEF (%) 34.6 ± 8.2 34.9 ± 7.3 34.4 ± 9.1 .77
Treatment
ACEi/ARB 101 (100.0%) 51 (100%) 50 (100%) .21
β-Blocker 98 (97.0%) 50 (98%) 48 (96%) .55
MRA 29 (28.7%) 11 (22%) 18(36%) .11
Diuretic 67 (66.3%) 29 (57%) 38 (76%) .042*
Lipid-lowering drug 78 (77.2%) 38 (75%) 40 (80%) .51
Laboratory measurements
eGFR (mL min−1 1.73 m−2) 80.4 ± 16.5 85.1 ± 14.1 75.6 ± 17.5 .003*
NT-proBNP (pg/mL) 375.5 (201.5–808.3) 311.5 (195.0–515.0) 509.5 (270.0–1462.0) .002*
Creatinine (μmol/L) 90.0 ± 18.3 84.5 ± 13.1 95.5 ± 21.1 .002*
HbA1c (%) 5.9 (5.7–6.3) 5.9 (5.6–6.1) 6.0 (5.7–6.4) .093
Total cholesterol (mmol/L) 4.3 (3.7–4.9) 4.5 (3.9–5.2) 3.9 (3.5–4.5) .012*
LDL (mmol/L) 2.4 (2.0–3.1) 2.6 (2.1–3.3) 2.3 (1.8–2.9) .005*
Albumin (g/L) 44.0 (43.0–46.0) 45.0 (43.0–47.0) 44.0 (42.0–46.0) .017*
Urea (mmol/L) 6.3 (5.5–7.5) 6.1 (5.2–6.8) 6.9 (5.9–7.8) .039*
PRA (nmol/L/h) 5.2 (1.5–19.7) 4.3 (1.5–15.3) 7.0 (1.4–28.7) .34
Aldosterone (nmol/L) 0.2 (0.1–0.4) 0.2 (0.1–0.3) 0.3 (0.1–0.4) .036*
FGF-23 (RU/mL) 112.8 (92.5–164.0) 105.0 (85.4–120.5) 136.6 (103.5–184.2) <.001*
Gal-3 (ng/μL) 16.6 (14.5–19.3) 15.6 (13.4–17.6) 18.4 (15.8–20.4) <.001*
hsTnT (pg/mL) 4.3 (3.0–11.5) 3.0 (3.0–6.5) 8.4 (3.0–17.2) <.001*
ICTP (μg/L) 3.4 (2.6–4.3) 3.2 (2.3–3.8) 3.8 (2.8–4.5) .016*
PIIINP (ug/L) 10.5 (7.0–15.5) 10.0 (7.0–13.0) 11.0 (8.5–19.0) .10
Data are presented as mean ± SD for normally distributed data, as median (interquartile range) for nonnormally distributed data, and as n (%) for categoric
variables. HE4, human epididymis protein; SBP, systolic blood pressure; DBP, diastolic blood pressure; BMI, body mass index; NYHA, New York Heart
Assocation; LVEF, left ventricular ejection fraction; ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; MRA, mineralo-
corticoid receptor antagonist, eGFR, estimated glomerular filtration rate; NT-proBNP, N-terminal prohormone of B-type natriuretic peptide; HbA1c, glycated
hemoglobin; LDL, low-density lipoprotein; PRA, plasma renin activity; FGF-23, fibroblast growth factor 23; Gal-3, galectin-3; hsTnT, high-sensitivity tro-
ponin T; ICTP, collagen type 1 cross-linked telopeptides; PIIINP, protocollagen 3 N-terminal propeptide.
*P < .05.
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were included as independent explanatory variables of HE4
levels in the multivariable model. Patients with CHF with
above-median HE4 levels had a higher risk of reaching the
composite end point. Similar results were obtained with HE4
levels above the 95% percentile of the healthy control group
(103.3 pmol/L; data not shown). Thus, in patients with CHF,
HE4 levels are associated with HF severity and kidney func-
tion and are predictive for HF outcome (HF rehospitalization
Table 3. Relationship Between HE4 Levels and Baseline Characteristics
Characteristic Univariable Sβ R2 P Value Age-Adjusted Sβ R2 P Value
Age 0.433 0.180 <.001*
Female sex −0.255 0.056 .010* −0.238 0.229 .008*
SBP −0.031 −0.009 .759 −0.109 0.183 .236
DBP −0.013 −0.010 .900 −0.006 0.171 .944
Hypertension 0.213 0.036 .033* 0.154 0.195 .093
BMI −0.027 −0.009 .785 −0.003 0.171 .972
Diabetes 0.217 0.038 .029* 0.253 0.224 .011*
Current smoker 0.178 0.022 .075 0.262 0.239 .004*
Myocardial infarction 0.145 0.011 .148 0.161 0.198 .076
Hypercholesterolemia −0.057 −0.007 .573 −0.042 0.173 .643
Heart failure history
NYHA functional class (II vs III) 0.337 0.105 .001* 0.267 0.241 .003*
LVEF 0.008 −0.010 .941 −0.023 0.172 .802
Treatment
ACEi/ARB 0.000 0.000 1.000 0.000 0.000 1.000
β-Blocker −0.103 0.001 .307 −0.074 0.177 .418
MRA 0.153 0.014 .126 0.229 0.223 .012*
Diuretics 0.120 0.004 .233 0.117 0.185 .198
Lipid-lowering drug 0.099 0.000 .324 0.066 0.176 .468
Laboratory measurements
eGFR −0.431 0.178 <.001* −0.289 0.236 .005*
NT-proBNP† 0.440 0.185 <.001* 0.314 0.252 <.001*
Creatinine 0.509 0.252 <.001* 0.415 0.330 .001*
HbA1c† 0.220 0.039 .028* 0.194 0.208 .033*
Total cholesterol† −0.256 0.056 .010* −0.195 0.208 .034*
LDL† −0.282 0.070 .004* −0.227 0.221 .013*
Albumin −0.234 0.045 .019* −0.073 0.174 .464
Urea† 0.347 0.112 <.001* 0.199 0.203 .049
PRA† 0.146 0.011 .151 0.212 0.212 .022*
Aldosterone† 0.244 0.050 .014* 0.244 0.233 .007*
FGF-23† 0.422 0.170 <.001* 0.341 0.286 <.001*
Gal-3† 0.466 0.210 <.001* 0.366 0.294 <.001*
hsTnT† 0.520 0.263 <.001* 0.404 0.294 <.001*
ICTP† 0.421 0.168 <.001* 0.316 0.253 .001*
PIIINP† 0.275 0.066 .006* 0.133 0.174 .186
Sβ, standardized beta coefficient, a reflection of the change in dependent variable for 1 SD change in the independent variable. Other abbreviations as in Table 2.
*P < .05.
†Log-transformed.
Table 4. Multivariable Models
Characteristic β ± SE Sβ P Value
Multivariable model
Creatinine 0.549 ± 0.141 0.317 <.001*
Gal-3† 2.678 ± 0.585 0.347 <.001*
hsTnT† 9.943 ± 0.585 0.258 .003*
Current smoker 15.935 ± 5.249 0.215 .003*
NT-proBNP† 5.268 ± 2.489 0.173 .037*
Clinical model
Creatinine 0.494 ± 0.140 0.328 .001*
Gal-3† 2.945 ± 0.599 0.381 <.001*
hsTnT† 10.154 ± 3.469 0.263 .005*
Current smoker 12.957 ± 5.383 0.175 .019*
NT-proBNP† 7.087 ± 2.596 0.233 .008*
Age −0.219 ± 0.286 −0.070 .447*
Ischemic etiology 10.903 ± 5.172 0.158 .038*
LVEF 0.536 ± 0.281 0.144 .061
Model including HE4-associated factors: R2 = 0.595. Model including HE4-
associated factors and HF risk factors: R2 = 0.611. Abbreviations as in Tables
2 and 3.
*P < .05.
†Log-transformed.
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Fig. 2. Kaplan-Meier curves in patients with chronic heart failure
and human epididymis protein 4 (HE4) levels above and below the
median for the composite end point (heart failure hospitalization or
all-cause mortality). P < .001.
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or all-cause mortality). Moreover, from the AUC analysis, we
can conclude that solitary serum HE4 levels are a good pre-
dictor of HF outcome. The added value of HE4 to the
multivariable model, including known HF biomarkers such as
NT-proBNP was, however, not significant. This may not be sur-
prising, because these markers in the multivariable model
predicted 59.5% of the variance in HE4 level and are thus
strongly associated. Much more outcome events may proba-
bly be needed to provide adequate statistical power to test
whether a new risk marker adds prognostic information to es-
tablished risk factors in a multivariable model.24 Nevertheless,
40% of HE4 variance is still unexplained and therefore HE4
levels may provide additional information about a subset of
patients and may have additional value for patient stratifica-
tion. For such reasons, Gal-3 and sST2 biomarkers have been
included into the AHA guidelines to potentially provide ad-
ditional risk stratification,8 even though for those biomarkers
it is not yet clear in what characteristics these patients differ
exactly. In our opinion this is a first step that may pave the way
for further investigations in HE4 and CHF and may one day
help in HF risk stratification and therapeutic treatment. Finally,
we note that, compared with our previous AHF study,12 HE4
levels were lower in the present study with optimally treated
CHF patients. We believe this strengthens the statement that
HE4 levels are correlated with HF severity. It is tempting to
suggest that HE4 levels increase in acute decompensated HF
and decline when the situation stabilizes and therefore that HE4
could also be a marker for treatment. This hypothesis should
be tested in an AHF study with subsequent follow-up.
HE4 and Fibrosis
Although the exact function of HE4 is still unknown, HE4
sequence shows similarity to proteinase inhibitors, which sug-
gests a functional role of HE4 in fibrosis formation,13,17 and
in the kidney it has been shown that that fibroblast-derived
HE4 is a mediator of fibrosis.18 In a mouse model of renal
fibrosis, mice treated with HE4-neutralizing antibodies showed
reduced renal fibrosis.18 In the present study, correlations of
HE4 with HF biomarkers of fibrosis were found, of which
Gal-3 showed the strongest correlation. Fibrosis and HF de-
velopment are closely linked, and HE4 has been associated
with processes of fibrosis.18 Therefore, increased levels of HE4
in HF could potentially promote organ fibrosis and/or play
a role in fibrosis-induced end-organ damage in HF. Because
neutralizing HE4 results in less renal fibrosis in mouse models
of renal diseases,18 we speculate that HE4 could constitute
a potential target to reduce fibrosis in HF.
Study Limitations
A limitation of this study is the relatively small sample size,
a single-point assessment, and the high percentage of male
subjects. Nevertheless, we demonstrate a difference in HE4
levels between patients with HF and control subjects. Control
group samples and CHF samples were from 2 different studies,
and the control group was composed from the PREVEND
study, which consists predominantly of patients with minor
microalbuminuria. However, the median HE4 level of the
control group was in the same range as previously reported
normal values.14,23
Conclusion
HE4 levels are increased in patients with CHF and corre-
late with HF severity, NT-proBNP levels, and renal function.
HE4 levels are independently associated with outcome.
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